Due to the crucial role of HIF-1a in regulating sorafenib resistance, previous studies have demonstrated that a dozen of drugs improve sorafenib resistance in HCC by indirect targeting HIF-1a. Here, HIF1A is linked to hepatocellular carcinoma.